Physician profile
John F Almquist
NPI 1568460467
$18,723.72
in general payments reported to CMS, 2019-2025
35 companies · $225 in 2025
The $225 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,132 · 2020: $2,231 · 2021: $3,019 · 2022: $2,933 · 2023: $2,977 · 2024: $3,206 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,408.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,178.37 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $1,992.64 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $1,792.21 | 2019-2025 | |
| Novo Nordisk INC | $1,775.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $1,410.01 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $1,291.75 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Allergan, INC. | $1,178.00 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $1,059.80 | 2019-2025 | Camzyos, Eliquis, Reblozyl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $958.93 | 2019-2025 | Jardiance, Synjardy |
| Amgen INC. | $833.99 | 2019-2024 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $770.37 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $650.55 | 2019-2025 | Vaqta, Gardasil 9, M-M-R II |
| Sanofi-Aventis U.S. LLC | $214.40 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $196.38 | 2021-2025 | |
| Amarin Pharma, INC. | $183.33 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $162.05 | 2020-2023 | Livalo, Seglentis |
| Indivior INC. | $124.75 | 2019 | |
| Alkermes, INC. | $120.90 | 2019 | |
| Novartis Pharmaceuticals Corporation | $109.98 | 2021-2022 | |
| Exact Sciences Corporation | $100.11 | 2023-2025 | Cologuard Collection Kit |
| Janssen Scientific Affairs, LLC | $95.50 | 2019 | |
| Genzyme Corporation | $85.00 | 2019 | |
| Astellas Pharma US INC | $58.06 | 2020-2021 | |
| Shield Therapeutics INC | $55.85 | 2023 | Accrufer |
| Abbott Laboratories | $54.30 | 2022-2023 | Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.34 | 2020-2023 | Xifaxan |
| Ironshore Pharmaceuticals INC. | $39.80 | 2019 | |
| Almatica Pharma LLC | $35.64 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $35.29 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $29.03 | 2022-2023 | Quviviq |
| Boston Scientific Corporation | $19.48 | 2024 | Watchman Flx |
| Mylan Specialty L.P. | $17.94 | 2024 | Yupelri |
| Shire North American Group INC | $15.63 | 2019 | |
| Eisai INC. | $12.48 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Almquist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.